Anadys Pharmaceuticals (ANDS) Posts Wider than Expected Q3 Loss
Tweet
Share
E-mailGet Alerts ANDS Hot Sheet
Price: $3.70 --0%
Financial Fact:
Net loss per share, basic and diluted: -0.16
Today's EPS Names:
OTLK, EGRX, MOVE, More
Financial Fact:
Net loss per share, basic and diluted: -0.16
Today's EPS Names:
OTLK, EGRX, MOVE, More
Join SI Premium – FREE
Anadys Pharmaceuticals, Inc. (NASDAQ: ANDS) reported Q3 EPS of ($0.16), $0.02 worse than the analyst estimate of ($0.14).
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
- Edible Garden AG (EDBL) Reports Q2 Loss of $18.79
- Rein Therapeutics Inc. (RNTX) Tops Q2 EPS by 39c
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
